Cancers, Volume 17, Issue 8
2025 April-2 - 129 articles
Cover Story: ESR1 resistance mutations are common in patients with breast cancer previously treated with anti-hormonal therapy. Elacestrant, an FDA- and EMA-approved oral drug, targets ESR1-positive tumors. Therefore, it is necessary to develop and validate sensitive assays to detect ESR1 mutations that allow clinicians to determine eligibility for treatment with Elacestrant. We use real-world patient data from two pathology laboratories in Germany to highlight the rarity of ESR1 mutations in hormonal therapy-naïve patients (n = 5106), compare molecular detection approaches, and demonstrate the general distribution and pattern of occurrence of these mutations in patients with breast cancer as detected by a novel NGS panel (n = 354). Our results are intended to inform future practices and approaches to molecular diagnostics used in making therapeutic decisions. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
